These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37021589)

  • 21. The basal forebrain volume reduction detected by MRI does not necessarily link with the cholinergic neuronal loss in the Alzheimer's disease mouse model.
    Zhou XA; Ngiam G; Qian L; Sankorrakul K; Coulson EJ; Chuang KH
    Neurobiol Aging; 2022 Sep; 117():24-32. PubMed ID: 35640461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia.
    Grothe MJ; Schuster C; Bauer F; Heinsen H; Prudlo J; Teipel SJ
    J Neurol; 2014 Oct; 261(10):1939-48. PubMed ID: 25059393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment - A Multicenter DTI and Volumetry Study.
    Brueggen K; Dyrba M; Barkhof F; Hausner L; Filippi M; Nestor PJ; Hauenstein K; Klöppel S; Grothe MJ; Kasper E; Teipel SJ
    J Alzheimers Dis; 2015; 48(1):197-204. PubMed ID: 26401940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased functional connectivity between nucleus basalis of Meynert and amygdala in cognitively intact elderly along the Alzheimer's continuum.
    Zeng Q; Qiu T; Li K; Luo X; Wang S; Xu X; Liu X; Hong L; Li J; Huang P; Zhang M;
    Neuroimage Clin; 2022; 36():103256. PubMed ID: 36451361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRI-based basal forebrain atrophy and volumetric signatures associated with limbic TDP-43 compared to Alzheimer's disease pathology.
    Teipel S; Grothe MJ;
    Neurobiol Dis; 2023 May; 180():106070. PubMed ID: 36898615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers.
    Howell JC; Watts KD; Parker MW; Wu J; Kollhoff A; Wingo TS; Dorbin CD; Qiu D; Hu WT
    Alzheimers Res Ther; 2017 Nov; 9(1):88. PubMed ID: 29096697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome.
    Neale N; Padilla C; Fonseca LM; Holland T; Zaman S
    Neuroimage Clin; 2018; 17():263-271. PubMed ID: 29159043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome.
    Lleó A; Zetterberg H; Pegueroles J; Karikari TK; Carmona-Iragui M; Ashton NJ; Montal V; Barroeta I; Lantero-Rodríguez J; Videla L; Altuna M; Benejam B; Fernandez S; Valldeneu S; Garzón D; Bejanin A; Iulita MF; Camacho V; Medrano-Martorell S; Belbin O; Clarimon J; Lehmann S; Alcolea D; Blesa R; Blennow K; Fortea J
    Nat Commun; 2021 Jul; 12(1):4304. PubMed ID: 34262030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship Between General Cognition, Visual Assessed Cortical Atrophy, and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: A Cross-Sectional Study from a Chinese PUMCH Cohort.
    Mao C; Sha L; Li J; Huang X; Chu S; Lei D; Wang J; Dong L; Liu C; Xu Q; Peng B; Gao J
    J Alzheimers Dis; 2021; 82(1):205-214. PubMed ID: 34024840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffusion MRI detects basal forebrain cholinergic abnormalities in the 3xTg-AD mouse model of Alzheimer's disease.
    Falangola MF; Nie X; Ward R; Dhiman S; Voltin J; Nietert PJ; Jensen JH
    Magn Reson Imaging; 2021 Nov; 83():1-13. PubMed ID: 34229088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease.
    Teipel SJ; Fritz HC; Grothe MJ;
    Neurology; 2020 Sep; 95(10):e1301-e1311. PubMed ID: 32631924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
    Rafii MS; Donohue MC; Matthews DC; Muranevici G; Ness S; O'Bryant SE; Rissman RA
    J Alzheimers Dis; 2019; 70(1):131-138. PubMed ID: 31156181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease.
    Grothe M; Heinsen H; Teipel S
    Neurobiol Aging; 2013 Apr; 34(4):1210-20. PubMed ID: 23158764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study.
    Montoliu-Gaya L; Alcolea D; Ashton NJ; Pegueroles J; Levin J; Bosch B; Lantero-Rodriguez J; Carmona-Iragui M; Wagemann O; Balasa M; Kac PR; Barroeta I; Lladó A; Brum WS; Videla L; Gonzalez-Ortiz F; Benejam B; Arranz Martínez JJ; Karikari TK; Nübling G; Bejanin A; Benedet AL; Blesa R; Lleó A; Blennow K; Sánchez-Valle R; Zetterberg H; Fortea J
    EBioMedicine; 2023 Apr; 90():104547. PubMed ID: 37002988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of white matter hyperintensities in Down syndrome.
    Morcillo-Nieto AO; Zsadanyi SE; Arriola-Infante JE; Carmona-Iragui M; Montal V; Pegueroles J; Aranha MR; Vaqué-Alcázar L; Padilla C; Benejam B; Videla L; Barroeta I; Fernandez S; Altuna M; Giménez S; González-Ortiz S; Bargalló N; Ribas L; Arranz J; Torres S; Iulita MF; Belbin O; Camacho V; Alcolea D; Lleó A; Fortea J; Bejanin A
    Alzheimers Dement; 2024 Aug; ():. PubMed ID: 39087352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.
    Ray NJ; Bradburn S; Murgatroyd C; Toseeb U; Mir P; Kountouriotis GK; Teipel SJ; Grothe MJ
    Brain; 2018 Jan; 141(1):165-176. PubMed ID: 29228203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal Alzheimer's Degeneration Reflects the Spatial Topography of Cholinergic Basal Forebrain Projections.
    Schmitz TW; Mur M; Aghourian M; Bedard MA; Spreng RN;
    Cell Rep; 2018 Jul; 24(1):38-46. PubMed ID: 29972789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Independent and additive contribution of white matter hyperintensities and Alzheimer's disease pathology to basal forebrain cholinergic system degeneration.
    Kindler C; Upadhyay N; Bendella Z; Dorn F; Keil VC; Petzold GC
    Neuroimage Clin; 2023; 39():103477. PubMed ID: 37478584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of β-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra.
    Yoo HS; Jeon S; Cavedo E; Ko M; Yun M; Lee PH; Sohn YH; Grothe MJ; Teipel S; Hampel H; Evans AC; Ye BS
    Neurology; 2022 Mar; 98(9):e947-e957. PubMed ID: 34969939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.